



Omnicia Inc. Announces the Release of OmniVIEW™ – An eCTD Viewer that Supports Submission Validation, Viewing, Navigation and Lifecycle Management.

South San Francisco, CA – October 10, 2006 – Omnicia, the emerging force in electronic submission publishing, announced today the release of OmniVIEW™ - an intuitive, multidimensional product that allows users to view eCTDs and the submission lifecycle.

As the eCTD becomes the submission choice for biotech and pharmaceutical companies, these organizations must develop regulatory and technology implementation strategies to ensure success. Risk of obtaining a Refusal to File (RTF) is high if an organization does not have the right tool to ensure that the eCTD produced satisfies ICH and regional specifications. OmniVIEW™ eliminates this risk!

“Shooting at moving targets and rushing products to market is not Omnicia’s style. In the publishing space, we continue to see ample evidence that this philosophy only leads to repackaging of existing technology deemed unacceptable by the user community. Feedback from seasoned electronic publishers and technical discussions with US and EU regulatory agencies were the foundation for OmniVIEW™.” said Reuben K. Jenkins, President and CEO of Omnicia.

OmniVIEW™ works in concert with Omnicia’s ground-breaking electronic publishing tool, OmniFILE™ as well as eCTD output from other publishing systems.

“It would be ridiculous to ignore the electronic publishing landscape. There is an extensive installed base that could benefit from eCTD viewing capability. OmniVIEW™ demonstrates it is possible to develop a product that supports companies at any stage of their electronic publishing lifecycle.” said Peachy Dimalig, Omnicia’s Chief Operating Officer.

With the addition of OmniVIEW™ to the Omnicia authoring and publishing suite, biotech and pharmaceutical companies no longer need to purchase multiple products to meet their electronic publishing needs. Omnicia offers the only fully integrated electronic publishing solution that supports batch hyperlinking at the MS Word and PDF source document level.

The Omnicia solution publishes drug development reports, Investigational New Drug Applications (INDs), Clinical Trials Applications (CTAs), Biologic License Applications (BLAs), New Drug Applications (NDAs), Abbreviated New Drug Applications (aNDAs), New Drug Submissions (NDS), and Marketing Authorisation Applications (MAAs). It creates everything from paper submissions with tabs, special sheets, and automated table of contents to full-blown Electronic Common Technical Documents (eCTDs) with the XML backbone.

About Omnicia Inc.

Omnicia was founded in October of 2001 and is a privately-held corporation. After working for years as the publishing team for a major pharmaceutical company, the founders decided that less costly, more efficient systems and products were needed in the submissions publishing arena. By combining professional services and product software development, Omnicia was able to continue to stay close to the changing needs of the user community while applying the “lessons learned” to improve its product offering. For details on Omnicia’s products and services, please visit our web site at www.omniciainc.com.